跳至主要内容
临床试验/NCT00596999
NCT00596999Unknown不适用

A Single-Arm Study to Assess the Safety of Transplantation With Umbilical Cord Blood Augmented With Human Placental-Derived Stem Cells From Partially Matched Related Donors in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders

Celgene Corporation1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2007年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
6
试验地点
1
主要终点
Incidence of GVHD, time to engraftment and survival

研究概览

简要总结

To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or nonmalignant disorders potentially curable with stem cell transplantation and to assess potential restoration of normal hematopoiesis and immune function in subjects with these disorders

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
— 至 55 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • suitable UCB collected from partially or fully HLA matched related donor
  • subject requires umbilical cord transplantation

排除标准

  • any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • major anticipated illness or organ failure incompatible with survival from stem cell transplant

结局指标

主要结局

Incidence of GVHD, time to engraftment and survival

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验